Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by JEFFREY E LEE and MATTHEW HAROLD KATZ.
JEFFREY E LEE
Connection Strength
2.892
MATTHEW HAROLD KATZ
  1. Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. Am J Surg Pathol. 2015 Oct; 39(10):1395-403.
    View in: PubMed
    Score: 0.136
  2. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer. J Am Coll Surg. 2014 Jul; 219(1):111-20.
    View in: PubMed
    Score: 0.122
  3. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 2014 Jan; 18(1):16-24; discussion 24-5.
    View in: PubMed
    Score: 0.120
  4. Race does not impact pancreatic cancer treatment and survival in an equal access federal health care system. Ann Surg Oncol. 2013 Dec; 20(13):4073-9.
    View in: PubMed
    Score: 0.118
  5. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014 May; 16(5):430-8.
    View in: PubMed
    Score: 0.118
  6. Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol. 2013 Jul; 20(7):2197-203.
    View in: PubMed
    Score: 0.114
  7. Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques. J Am Coll Surg. 2012 Aug; 215(2):e11-8.
    View in: PubMed
    Score: 0.110
  8. Clinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancer. Arch Surg. 2012 Jun; 147(6):513-9.
    View in: PubMed
    Score: 0.108
  9. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg. 2012 Sep; 16(9):1696-704.
    View in: PubMed
    Score: 0.108
  10. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012 Dec 01; 118(23):5749-56.
    View in: PubMed
    Score: 0.108
  11. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford). 2012 Jun; 14(6):365-72.
    View in: PubMed
    Score: 0.106
  12. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 2012 Jun; 19(6):2045-53.
    View in: PubMed
    Score: 0.106
  13. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg. 2012 Jan; 16(1):68-78; discussion 78-9.
    View in: PubMed
    Score: 0.104
  14. Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial. Ann Surg Oncol. 2011 Dec; 18(13):3615-22.
    View in: PubMed
    Score: 0.101
  15. Borderline resectable pancreatic cancer: what have we learned and where do we go from here? Ann Surg Oncol. 2011 Mar; 18(3):608-10.
    View in: PubMed
    Score: 0.099
  16. Current status of adjuvant therapy for pancreatic cancer. Oncologist. 2010; 15(11):1205-13.
    View in: PubMed
    Score: 0.097
  17. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010 Jul; 17(7):1794-801.
    View in: PubMed
    Score: 0.092
  18. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009 Apr; 16(4):836-47.
    View in: PubMed
    Score: 0.086
  19. Anatomy of the superior mesenteric vein with special reference to the surgical management of first-order branch involvement at pancreaticoduodenectomy. Ann Surg. 2008 Dec; 248(6):1098-102.
    View in: PubMed
    Score: 0.085
  20. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008 May; 206(5):833-46; discussion 846-8.
    View in: PubMed
    Score: 0.081
  21. Rapid assessment of technical competency: the?8-min suture test. J Surg Res. 2016 Jan; 200(1):46-52.
    View in: PubMed
    Score: 0.033
  22. Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma. Hum Pathol. 2015 Sep; 46(9):1315-22.
    View in: PubMed
    Score: 0.033
  23. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Phys Biol. 2014 Nov 26; 11(6):065002.
    View in: PubMed
    Score: 0.032
  24. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann Surg Oncol. 2015 Apr; 22(4):1168-75.
    View in: PubMed
    Score: 0.032
  25. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest. 2014 Apr; 124(4):1525-36.
    View in: PubMed
    Score: 0.031
  26. The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy. Arch Pathol Lab Med. 2013 Nov; 137(11):1619-26.
    View in: PubMed
    Score: 0.030
  27. Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification. J Gastrointest Surg. 2014 Jan; 18(1):146-55; discussion 155-6.
    View in: PubMed
    Score: 0.030
  28. Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. J Gastrointest Surg. 2014 Feb; 18(2):269-78; discussion 278.
    View in: PubMed
    Score: 0.030
  29. Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma. Histopathology. 2013 Dec; 63(6):841-51.
    View in: PubMed
    Score: 0.030
  30. Predicting the risks of venous thromboembolism versus post-pancreatectomy haemorrhage: analysis of 13,771 NSQIP patients. HPB (Oxford). 2014 Apr; 16(4):373-83.
    View in: PubMed
    Score: 0.029
  31. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann Oncol. 2013 Sep; 24(9):2349-53.
    View in: PubMed
    Score: 0.029
  32. Prolonged endoscopic loop ligation for removal of gastrointestinal tumors. Endoscopy. 2013; 45 Suppl 2 UCTN:E69-70.
    View in: PubMed
    Score: 0.029
  33. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. Ann Surg Oncol. 2013 Dec; 20 Suppl 3:S500-8.
    View in: PubMed
    Score: 0.028
  34. Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Hum Pathol. 2013 Jun; 44(6):1024-30.
    View in: PubMed
    Score: 0.028
  35. Solid pseudopapillary neoplasm of the pancreas with prominent atypical multinucleated giant tumour cells. Histopathology. 2013 Feb; 62(3):465-71.
    View in: PubMed
    Score: 0.028
  36. A high positive lymph node ratio is associated with distant recurrence after surgical resection of ampullary carcinoma. J Gastrointest Surg. 2012 Nov; 16(11):2056-63.
    View in: PubMed
    Score: 0.028
  37. Fear of cancer recurrence after curative pancreatectomy: a cross-sectional study in survivors of pancreatic and periampullary tumors. Ann Surg Oncol. 2012 Dec; 19(13):4078-84.
    View in: PubMed
    Score: 0.027
  38. Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2012 Aug; 21(8):1336-43.
    View in: PubMed
    Score: 0.027
  39. Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. J Am Coll Surg. 2012 Jul; 215(1):41-51; discussion 51-2.
    View in: PubMed
    Score: 0.027
  40. Risk of venous thromboembolism outweighs post-hepatectomy bleeding complications: analysis of 5651 National Surgical Quality Improvement Program patients. HPB (Oxford). 2012 Aug; 14(8):506-13.
    View in: PubMed
    Score: 0.027
  41. Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy. Am J Surg Pathol. 2012 Apr; 36(4):552-9.
    View in: PubMed
    Score: 0.027
  42. Serum brain naturietic peptide measurements reflect fluid balance after pancreatectomy. J Am Coll Surg. 2012 May; 214(5):778-87.
    View in: PubMed
    Score: 0.027
  43. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2012 Mar; 36(3):409-17.
    View in: PubMed
    Score: 0.027
  44. Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2012 Aug 01; 118(15):3801-11.
    View in: PubMed
    Score: 0.026
  45. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol. 2012 Jan; 16(1):29-37.
    View in: PubMed
    Score: 0.026
  46. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. 2012 Jun 15; 118(12):3182-90.
    View in: PubMed
    Score: 0.026
  47. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2012 Jan 01; 118(1):268-77.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.